Article
Pathology
Ayaka Katayama, Islam M. Miligy, Sho Shiino, Michael S. Toss, Karim Eldib, Sasagu Kurozumi, Cecily M. Quinn, Nahla Badr, Ciara Murray, Elena Provenzano, Grace Callagy, Cian Martyn, Rebecca Millican-Slater, Colin Purdie, Dave Purnell, Sarah E. Pinder, Tetsunari Oyama, Abeer M. Shaaban, Ian Ellis, Andrew H. S. Lee, Emad A. Rakha
Summary: The response of HER2-positive breast cancer patients to anti-HER2 targeted therapy varies, with HER2 status discordance potentially occurring after neoadjuvant treatment. Results indicate that HER2 IHC 3+ and histological grade 3 are independent predictors of pathological complete response following neoadjuvant anti-HER2 therapy.
Article
Oncology
G. Griguolo, G. Serna, T. Pascual, R. Fasani, X. Guardia, N. Chic, L. Pare, S. Pernas, M. Munoz, M. Oliveira, M. Vidal, A. Llombart-Cussac, J. Cortes, P. Galvan, B. Bermejo, N. Martinez, R. Lopez, S. Morales, I Garau, L. Manso, J. Alarcon, E. Martinez, P. Villagrasa, A. Prat, P. Nuciforo
Summary: In HER2+ breast cancer, changes in the density of immune cells in the tumor microenvironment after anti-HER2 treatment, particularly those interacting spatially with tumor cells, are associated with treatment response. Furthermore, patients achieving pathologic complete response show a consistent decrease in stromal tumor-infiltrating lymphocytes (sTILs) post-surgery, while residual tumors often remain inflamed, suggesting a progressive loss of T cell function. Understanding the implications of the resulting immunosuppressive microenvironment is crucial for developing effective strategies for early-stage HER2+ breast cancer therapy.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Elli-Noora Hannikainen, Johanna Mattson, Peeter Karihtala
Summary: Retrospective data analysis of 119 patients with HER2-positive breast cancer treated with neoadjuvant systemic treatment showed that achieving a pathological complete response (pCR) was associated with better prognosis, while moderate immunohistochemical HER2 expression was associated with worse prognosis.
Article
Multidisciplinary Sciences
Sandra Orru, Emanuele Pascariello, Barbara Pes, Vincenzo Rallo, Raffaele Barbara, Marta Muntoni, Francesca Notari, Gianfranco Fancello, Cristina Mocci, Maria Rosaria Muroni, Paolo Cossu-Rocca, Andrea Angius, Maria Rosaria De Miglio
Summary: In this study, the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in HER2+ breast cancer patients receiving trastuzumab-based neoadjuvant chemotherapy was evaluated. The study found that a high tumoral pathological complete response rate is associated with a high percentage of infiltrating immune cells and right-sided tumors, which reduce distant metastasis and improve survival. HER2 protein expression levels and tumor laterality emerge as strong predictors of tumoral pathological complete response.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Tomas Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Nuria Chic, Maria Vidal, Barbara Adamo, Montserrat Munoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Pare, Patricia Galvan, Lisa A. Carey, CharlesM. Perou, Aleix Prat
Summary: In HR+/HER2+ breast cancer, the PAM50-based CES score can predict sensitivity to chemo-endocrine therapy and provide additional prognostic information beyond intrinsic subtype and clinicopathologic characteristics. High CES is associated with lower pCR probability and better DFS.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Chihwan Cha, Sung Gwe Ahn, Dooreh Kim, Janghee Lee, Soeun Park, Soong June Bae, Jee Ye Kim, Hyung Seok Park, Seho Park, Seung Il Kim, Byeong-Woo Park, Joon Jeong
Summary: Adding pertuzumab to chemotherapy increased the axillary pathological complete response (pCR) rate in patients with clinically node-positive, HER2-positive breast cancer, while dual HER2 blockade did not elevate the axillary response. Breast pCR could be a strong predictor for axillary pCR in clinically node-positive patients treated with HER2-targeting therapy.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Young-Joon Kang, Se Jeong Oh, Soo Youn Bae, Eun-Kyu Kim, Young-Jin Lee, Eun Hwa Park, Joon Jeong, Heung Kyu Park, Young Jin Suh, Yong-Seok Kim
Summary: This study aimed to determine predictive factors for late survival in patients with HER2-positive breast cancer. It found that age, advanced tumor and lymph node stage, high histological grade, presence of lymphatic and vascular invasion, and hormone receptor-negative status were associated with poor overall survival. Node status had a more significant relationship with long-term prognosis than tumor stage in HER2-positive breast cancer patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Summary: The expression of HER2-low-positive shows high instability from primary breast cancer to residual disease after neoadjuvant treatment. HER2-low-positive expression in residual disease may guide personalized adjuvant treatment for high-risk patients in clinical trials.
Article
Oncology
Yihong Wang, Kamaljeet Singh, Don Dizon, Teresa Graves, Ali Amin, Evgeny Yakirevich
Summary: The study investigated the response of HER2-positive breast cancer patients to neoadjuvant chemotherapy, finding that HER2 protein expression is associated with predicting NAC response and long-term prognosis.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Kreina Sharela Vega Cano, David Humberto Marmolejo Castaneda, Santiago Escriva-de-Romani, Cristina Saura
Summary: Therapeutic advances have significantly improved the natural history of HER2-positive metastatic breast cancer. Double anti-HER2 blockade with a taxane is currently the best option in first-line, but T-DXd has emerged as the new standard in second-line. New treatments and combinations are being developed to address resistance and progress in these patients.
Article
Multidisciplinary Sciences
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Article
Oncology
Sanja Loeb, Eva Linsmeier, Saskia-Laureen Herbert, Tanja Schlaiss, Matthias Kiesel, Joerg Wischhusen, Jessica Salmen, Peter Kranke, Anne Quenzer, Florian Kurz, Claire Weiss, Elena Gerhard-Hartmann, Achim Woeckel, Joachim Diessner
Summary: The purpose of this study was to investigate the changes in HER2 subtypes between primary breast cancer and recurrent disease. The results showed that HER2 expression increased during the progression of the disease. This information is important for the development of therapeutic options for breast cancer patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Yuson Wang, Xiaoyan Liu, Keda Yu, Shouping Xu, Pengfei Qiu, Xinwen Zhang, Mozhi Wang, Yingying Xu
Summary: Neoadjuvant therapy (NAT) is recommended for patients with HER2+ BC who have a poor prognosis. The tumor immune microenvironment plays a significant role in the efficacy of NAT, but the relationship between tumor-infiltrating lymphocytes and the response to NAT in HER2+ BC is not yet clear. Our study classified the immune infiltration status of 295 patients into immune-rich and immune-poor phenotypes, with the immune-rich phenotype being significantly associated with pCR. We identified 10 genes that were correlated with both pCR and the immune phenotype, and constructed a generalized non-linear model that successfully predicted response to NAT.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Oncology
Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Summary: This study analyzed the safety and effectiveness data of pertuzumab in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia. The results revealed that pertuzumab showed effectiveness in surgical outcomes and the safety data align with previous clinical trials, without any new safety concerns.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Emergency Medicine
Kara L. Holloway-Kew, Tim R. Baker, Muhammad A. Sajjad, Mark A. Kotowicz, Patricia M. Livingston, Mustafa Khasraw, Sharon Hakkennes, Trisha L. Dunning, Susan Brumby, Richard S. Page, Alasdair G. Sutherland, Sharon L. Brennan-Olsen, Lana J. Williams, Julie A. Pasco
AUSTRALASIAN EMERGENCY CARE
(2020)
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Malinda Itchins, Mustafa Khasraw
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Review
Cell Biology
Hinda Najem, Mustafa Khasraw, Amy B. Heimberger
Summary: This article highlights the general resistance of brain tumors to immunotherapeutic agents and the important role of diverse immune cells in the immune microenvironment in the tumorigenesis process. Immune therapeutic combinations are identified as a crucial objective for future clinical studies.
Review
Oncology
Hao-Wen Sim, Evanthia Galanis, Mustafa Khasraw
Summary: New effective treatments for glioma are urgently needed, and PARP inhibitors are a promising option. They block the repair of DNA damage and may work synergistically with radiotherapy, chemotherapy, and immunotherapy. While low-grade gliomas have a better prognosis, recurrence and progression are still common.
Article
Biochemistry & Molecular Biology
Abhirami Venugopal, Agnes Michalczyk, Mustafa Khasraw, M. Leigh Ackland
Summary: Neuroendocrine neoplasms (NENs) are relatively rare tumors that occur primarily in the gastrointestinal tract and pancreas. The heterogeneity of these tumors presents challenges for diagnosis and treatment. This study identified differential expression of epithelial-mesenchymal transition (EMT) molecules in different tumor grades, suggesting their potential use in tumor stratification, prognosis, and therapeutic targeting.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Alexander Yuile, Joe Q. Wei, Aditya A. Mohan, Kelly M. Hotchkiss, Mustafa Khasraw
Summary: Gliomas are common and deadly brain tumors with limited treatment options. The complex interaction between glioma cells and non-cancerous cells in the brain tissue, as well as variations depending on specific mutations, play a crucial role in glioma development. Understanding these interactions and mutations is essential for identifying future treatments for gliomas.
Meeting Abstract
Oncology
Eric Thompson, Daniel Landi, Eric Thompson, Eric Lipp, Bea Balajonda, James Herndon, Evan Buckley, Charlene Flahiff, Denise Jaggers, Kristin Schroeder, Dina Randazzo, Annick Desjardins, Maggie Johnson, Katherine Peters, Mustafa Khasraw, Michael Malinzak, Duane Mitchell, David Ashley, John Sampson
Meeting Abstract
Oncology
Kyle Walsh, Joanne Xiu, Giselle Lopez, Daniel Landi, Zachary Reitman, Sandeep Mittal, Andrew Brenner, Ekokobe Fonkem, Santosh Kesari, Surasak Phuphanich, Herbert Newton, Manjari Pandey, Emil Lou, Michael Glantz, Ashley Sumrall, Erin Dunbar, Macarena De La Fuente, W. Michael Korn, Mustafa Khasraw, David Ashley
Meeting Abstract
Oncology
Meredith Buxton, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, Gary Gordon, Mustafa Khasraw, Andrew Lassman, Wenbin Lee, Michael Lim, Ingo Mellinghoff, James Perry, Erik Sulman, Kirk Tanner, Michael Weller, Patrick Wen, W. K. Alfred Yung, Timothy Cloughesy
Meeting Abstract
Oncology
Nicole Cort, Alex Broom, Katherine Kenny, Alexander Page, Jennifer Durling, Casey Brown, Eric Lipp, David Ashley, Kyle Walsh, Margaret Johnson, Mustafa Khasraw
Meeting Abstract
Oncology
Annick Desjardins, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, Stevie Threatt, Chevelle Bullock, James Herndon, Eric Lipp, John Sampson, Allan Friedman, Henry Friedman, David Ashley, Darell Bigner
Review
Medicine, General & Internal
Adrian Lee, Malmaruha Arasaratnam, David Lok Hang Chan, Mustafa Khasraw, Viive M. Howell, Helen Wheeler
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2020)
Meeting Abstract
Oncology
Timothy A. Yap, Panagiotis Konstantinopoulos, Melinda L. Telli, Smita Saraykar, J. Thaddeus Beck, Matthew D. Galsky, Jame Abraham, David R. Wise, Mustafa Khasraw, Gabor Rubovszky, Mikhail Dvorkin, Anil A. Joy, Mateusz Opyrchal, Daria Stypinski, Colombe Chappey, Ross Stewart, Rossano Cesari, Anita Scheuber, Aditya Bardia
Article
Oncology
Joseph Chan, Dasantha Jayamanne, Helen Wheeler, Mustafa Khasraw, Matthew Wong, Marina Kastelan, Lesley Guo, Michael Back
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2020)
Article
Medicine, Research & Experimental
Kevin J. Anderson, Aaron C. Tan, Jonathon Parkinson, Michael Back, Marina Kastelan, Allison Newey, Janice Brewer, Helen Wheeler, Amanda L. Hudson, Samirkumar B. Amin, Kevin C. Johnson, Floris P. Barthel, Roel G. W. Verhaak, Mustafa Khasraw
COLD SPRING HARBOR MOLECULAR CASE STUDIES
(2020)